Just before the stock market opened on Tuesday, President Donald Trump tweeted that he is working on “a new system” to reduce prices, adding that he’ll bring “competition” to the drug industry. It’s not the first time comments from Trump have had a big effect on pharmaceutical stocks, but he hasn’t gotten into specifics and investors aren’t sure how committed he is to doing something.
Category: Biotech
Life Technologies Corp. v. Promega Corp. and the Absent Presumption Against Extraterritoriality
Guest Post by Tim Holbrook, Professor of Law at Emory University School of Law. Professor Holbrook has written extensively on the extraterritorial application of U.S. patent law.
Trump’s H1-B Visa Crackdown Threatens Cutting-Edge U.S. Medicine
Amgen Inc. and Gilead Sciences Inc., as well as overseas companies with stateside operations, rely on the world’s best scientists and lower-level researchers with scarce expertise. A crackdown on visas for these workers could set back research, including the treatment of cancer, executives said.
Drug company fined $150 million for not reporting suspicious orders
A prescription drug wholesale company was handed a record fine Tuesday on allegations from U.S. regulators for not reporting suspicious orders of painkillers. McKesson Corporation will pay a $150 million fine and stop selling certain drugs in Colorado, Ohio, Florida and Michigan after it avoided its own internal systems to avoid inconsistent or outsize orders of drugs such as oxycodone and hydrocodone that are linked to the national opioid epidemic, the Department of Justice announced on Tuesday.
BRIEF-Vermillion, Aspira Labs receive formal FDA clarification…
* Mazor Robotics received purchase orders for 21 systems during fourth quarter 2016; full year system orders increased by 138 pct to all time record of 62 units Source text for Eikon: Further company coverage:
BRIEF-U.S. FDA approves supplemental New Drug Applications for three Type 2 diabetes medicines
WASHINGTON, Jan 4 U.S. Chief Justice John Roberts will no longer participate in a patent dispute at the Supreme Court involving a unit of Thermo Fisher Scientific Inc after he realized he owns about $175,000 of stock in the company, the court said on Wednesday.
Roberts recuses from patent case after discovering conflict
Supreme Court Chief Justice John Roberts says he will no longer participate in deciding a patent infringement case because he discovered he owns shares in the parent company of one of the parties. Roberts took part in arguments in the dispute between California-based Life Technologies Corp. and Wisconsin-based Promega Corp. on Dec. 6. A letter Wednesday from court clerk Scott Harris says Roberts has learned Life Technologies is owned by Massachusetts-based Thermo Fisher Scientific Inc., and Roberts owns shares valued at about $175,000.
Bragar Eagel & Squire, P.C. Reminds Investors of a Class Action…
Bragar Eagel & Squire, P.C. Reminds Investors of a Class Action Lawsuit Against Impax Laboratories, Inc. and the Lead Plaintiff Deadline of January 9, 2017 Bragar Eagel & Squire, P.C. Reminds Investors of a Class Action Lawsuit Against Impax Laboratories, Inc. and the Lead Plaintiff Deadline of January 9, 2017 Bragar Eagel & Squire, P.C. reminds investors that a class action lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all persons or entities who purchased or otherwise acquired Impax Laboratories, Inc. securities between February 20, 2014 and November 3, 2016 .
Teva: Good Value, Questionable Management?
One of the few sectors that has the potential to offer returns, in our opinion, is the pharmaceutical sector. Political claims sent pharma stocks into tailspin.